

Sarborg Leverages Signature AI Agents to File Substance of Matter Patent in Cystic Fibrosis Market

WILMINGTON, De – May 07, 2026 -- Sarborg Limited (“Sarborg” or the “Company”), today announced the filing of a new Substance of Matter (“SOM”) patent covering two established compounds within the cystic fibrosis market, further expanding its rapidly growing intellectual property portfolio.

This development follows the Company’s recent \$65 million acquisition of a portfolio of patented cannabinoid solid-form assets, highlighting Sarborg’s ability to identify, develop and secure high-value intellectual property within compressed timeframes.

The newly filed SOM patent was developed following analysis conducted using Sarborg’s proprietary Signature Agent and Multi-Agent platform. Through large-scale analysis of the Sarborg 1,600 Disease Database and Sarborg 1,700 Rare Disease Database, the Company deployed version one of its Sarborg Patent Agent, which supports the structuring of patent applications and aggregation of supporting evidence, in parallel with the traditional patent process. This approach enabled systematic identification of gaps in the therapeutic landscape, including expansion opportunities across additional indications, combination-based strategies, and areas of unmet need where current treatments exhibit limitations.

Despite the commercial success of existing therapies in this class, the Company identified several areas for improvement, particularly relating to physicochemical properties, including variable bioavailability which may result in inconsistent patient response. Sarborg’s approach focuses on developing improved forms designed to enhance consistency, stability and overall performance.

Using its agentic architecture, Sarborg progressed from initial signal identification through to patent filing in less than three weeks, demonstrating the speed and efficiency of its platform in generating commercially relevant intellectual property.

Sarborg - AI Driven Agent Process

From Signal to Filing in Less Than Three Weeks, Compared to Years.



Figure 1: High Level Agentic Process Overview

In addition to the core cystic fibrosis market, Sarborg’s Signature Agent has identified multiple additional high-potential therapeutic indications for these compounds, expanding the potential commercial opportunity beyond their current use.

The Company is further utilising its Signature Agent platform to analyse potential combination therapies involving these compounds. This includes systematic identification of complementary signatures and synergistic interactions, with the objective of generating additional patentable compositions and expanding the overall value of the asset.

The global cystic fibrosis therapeutics market is estimated to exceed \$10 billion annually and continues to grow, driven by increasing diagnosis rates, improved life expectancy, and

continued innovation in treatment approaches. Sarborg believes that its ability to enhance existing compounds and expand their applicability positions the Company to capture meaningful value within this market and adjacent indications.

This latest patent filing further strengthens Sarborg's position as a developer of differentiated, data-driven intellectual property across high-value pharmaceutical markets.

“This filing demonstrates the power of our Signature Agent and Multi-Agent platform and the initial use of version one patent agent to rapidly identify and execute on high-value opportunities,” said Mark Taylor, Director of Sarborg. “Within less than three weeks, we have expanded our portfolio across both cannabinoid and non-cannabinoid assets, reinforcing our ability to systematically generate proprietary intellectual property. We believe this approach represents a fundamentally new model for pharmaceutical innovation.”

About Sarborg Limited

Sarborg is an agentic AI signature intelligence business, built on the principle that signatures can function as a universal data language to identify, interpret, and generate high-value opportunities across multiple sectors. By analysing, matching, and learning from biological, chemical, and industrial signatures, Sarborg's agents create a continuously evolving network of intelligence-driven insights.

Investors & Media:

info@sarborg.com

www.sarborg.com